Table 1.

An overview of currently approved CAR-T products.

Category	Approval	Target	Indication
Tisagenlecleucel, tisa-cel	Aug. 2017	CD19	B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed after receiving at least second-line regimens; relapsed or refractory large B-cell lymphoma (second indication approved in 2018)
Axicabtagene	Oct. 2017	CD19	Treatment in adult patients with relapsed or refractory large B-cell lymphoma (LBCL) Adult patients with relapsed/refractory mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (ALL)
Ciloleucel, Axi-Cel Brexucabtagene autoleucel, KTE-X19	Jul. 2020	CD19
Lisocabtagenemaraleticel, L iso-cel	Feb. 2021	CD19	Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Idecabtagene Vicleucel, ide-cel	Mar. 2021	BCMA	Patients with relapsed/refractory multiple myeloma who have received four or more previous therapies, including immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies